GLORIA is an international investigator – initiated trial aiming to prove (or disprove) that the addition of chronic low dose glucocorticoids to current anti-rheumatic therapy is cost-effective and safe, in elderly patients with Rheumatoid Arthritis (RA). About 50% of patients are currently treated with this strategy.

GLORIA is funded by the EU Horizon 2020 Program. >> 


In Excelsis: The GLORIA Consortium Submits EU-Horizon Proposal for a New Trial and Project

We are pleased to announce that we have submitted an EU-Horizon 2020 proposal for a new trial and project to complement GLORIA. In Call PM10, the EU requested proposals for studies "evaluating existing health care in the adult population”. The call text was almost identical to the call text on the elderly in which GLORIA was successful. As more than half of the RA population is no
Read more

First patient included

It is with great pleasure that we announce that the first patient has now been included in GLORIA trial. The patient was included in VU University Medical Center, Amsterdam, Netherlands. GLORIA trial finally has lift off!
Read more